- Home
- PVL vs FLNA Comparison
PVL vs FLNA Comparison
Compare PVL & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PVL | FLNA |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.4M | 61.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PVL | FLNA |
|---|---|---|
| Price | $1.74 | $1.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 62.3K | ★ 369.2K |
| Earning Date | 03-20-2026 | 05-13-2026 |
| Dividend Yield | ★ 7.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.58 | $1.07 |
| 52 Week High | $2.04 | $2.03 |
Technical Indicators
Market Signals| Indicator | PVL | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 43.96 | 34.06 |
| Support Level | $1.60 | N/A |
| Resistance Level | $1.91 | $1.80 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 59.09 | 1.68 |
Price Performance
Historical ComparisonAbout PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About FLNA Filana Therapeutics Inc. Common Stock
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.